Ibandronate Sodium Hydrate

伊班膦酸钠

Report date: 2026/05/28 20:00:21
NME

Base Information

Drug NameIbandronate Sodium Hydrate
Drug Alias Name伊班膦酸钠水合物MethylpentylaminopropylideneIbandronate Sodium伊班膦酸钠一水合物伊班膦酸 +[24] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFarnesyl diphosphate synthase inhibitorsBone resorption factor inhibitors
TargetsBone resorption factorFarnesyl diphosphate synthase
Therapy Area/IndicationsFractures, BonePainHypercalcemia +[9] 
Global Approved IndicationsFractures, BoneHypercalcemiaOsteoporosis, Postmenopausal +[6] 
Approved Indications in ChinaHypercalcemiaOsteoporosis, Postmenopausal
Original Approved Country/TerritoryEU
Original Approved Date1996/06/25
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech IncF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaisho ToyamaChugai Pharmaceutical Co LtdColumbia University +[6] 
Inactive CompaniesRoche Pharma AgF. Hoffmann-La Roche AgF. Hoffmann-La Roche Ltd +[9] 
Active IndicationsFractures, BoneHypercalcemiaOsteoporosis, Postmenopausal +[6] 
Inactive IndicationsPainHematologic NeoplasmsBone Neoplasms

Other Information

ATC CodeM05BA06
Related LinksWikipediaDrugBankKEGG